Analyst Price Targets — PFE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 11:39 am | — | Guggenheim | $31.00 | $26.20 | TheFly | Pfizer price target lowered to $31 from $35 at Guggenheim |
| July 6, 2026 9:45 am | — | HSBC | $28.00 | $24.32 | TheFly | Pfizer downgraded to Hold from Buy at HSBC |
| May 27, 2026 1:46 pm | Michael Yee | UBS | $27.00 | $26.35 | StreetInsider | UBS Reiterates Neutral Rating on Pfizer (PFE) |
| May 14, 2026 11:51 am | Alexandria Hammond | Wolfe Research | $26.00 | $25.96 | TheFly | Pfizer price target raised to $26 from $25 at Wolfe Research |
| March 17, 2026 12:39 pm | Terence Flynn | Morgan Stanley | $27.00 | $27.06 | StreetInsider | Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive' |
| March 9, 2026 3:51 pm | Evan David Seigerman | BMO Capital | $30.00 | $26.49 | StreetInsider | BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data |
| February 24, 2026 9:05 pm | Trung Huynh | RBC Capital | $25.00 | $27.14 | StreetInsider | RBC Capital Starts Pfizer (PFE) at Underperform |
| February 19, 2026 9:17 pm | Emily Field | Barclays | $25.00 | $26.86 | TheFly | Pfizer initiated with an Underweight at Barclays |
| February 12, 2026 10:10 am | Narumi Nakagiri | Daiwa | $27.00 | $27.73 | TheFly | Pfizer downgraded to Neutral from Outperform at Daiwa |
| January 27, 2026 12:21 pm | — | Cantor Fitzgerald | $27.00 | $25.88 | TheFly | Pfizer price target raised to $27 from $24 at Cantor Fitzgerald |
Latest News for PFE
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
On CNBC's “Halftime Report Final Trades,” Kevin Simpson, founder and CEO of Capital Wealth Planning, picked Take-Two Interactive Software, Inc. (NASDAQ:TTWO).
Archer Investment Corp bought a new position in shares of Pfizer Inc. (NYSE: PFE) during the second quarter, according to its most recent filing with the SEC. The fund bought 73,546 shares of the biopharmaceutical company's stock, valued at approximately $1,771,000. Other institutional investors have also recently made changes to their positions in
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.